Aviptadil (Synonyms: Vasoactive Intestinal Peptide (human, rat, mouse, rabbit, canine, porcine)) |
| Katalog-Nr.GC14472 |
VIP (Mensch, Ratte, Maus, Kaninchen, Hund, Schwein) ist ein analoges vasoaktives intestinales Polypeptid (VIP) mit starker gefÄßerweiternder Wirkung.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 40077-57-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Aviptadil is a 28-amino acid neurotransmitter and a vasoactive intestinal polypeptide (VIP) analog. It has an effective vasodilator effect, can induce pulmonary vasodilation, and inhibit vascular smooth muscle cell proliferation and platelet aggregation[1, 2]. Aviptadil can be used in the study of pulmonary fibrosis, pulmonary hypertension, and respiratory failure caused by SARS-CoV-2[3].
In vivo, Aviptadil (500μg/kg) was intraperitoneally injected into rats with pulmonary hypertension (PHT) for 3 weeks, completely preventing and significantly reversing monocrotaline (MCT)-induced pulmonary hypertension PAH, and had a synergistic effect with bosentan[4]. Aviptadil (150μg/kg/day) was intraperitoneally injected into rats with pulmonary hypertension for 4 weeks, eliminating bronchial hyperresponsiveness (BHR) and having bronchodilating properties[5]. Aviptadil (3μg/kg) was intravenously injected into rats with lung transplantation model and improved the rat lung transplantation reperfusion injury[6].
References:
[1] Hu J, Xu Q, McTiernan C, et al. Novel targets of drug treatment for pulmonary hypertension[J]. American Journal of Cardiovascular Drugs, 2015, 15: 225-234.
[2] O'Callaghan D S, Jaïs X, Montani D, et al. A Look to the Future: Potential Therapeutic Options for Pulmonary Arterial Hypertension[J]. The Annals of Respiratory Medicine, 2009, 1(1): 1.
[3] Chakraborty D, Choudhury S, Lahiry S. Aviptadil-class effect of a synthetic vasoactive intestinal peptide as a treatment option in COVID-19 patients with severe respiratory failure[J]. Indian Journal of Respiratory Care, 2022, 11(1): 5-5.
[4] Hamidi S A, Lin R Z, Szema A M, et al. VIP and endothelin receptor antagonist: an effective combination against experimental pulmonary arterial hypertension[J]. Respiratory research, 2011, 12: 1-7.
[5] Habre W, Albu G, Janosi T Z, et al. Prevention of bronchial hyperreactivity in a rat model of precapillary pulmonary hypertension[J]. Respiratory research, 2011, 12: 1-8.
[6] Nagahiro I, Yano M, Boasquevisque C H, et al. Vasoactive intestinal peptide ameliorates reperfusion injury in rat lung transplantation[J]. The Journal of Heart and Lung Transplantation: the Official Publication of the International Society for Heart Transplantation, 1998, 17(6): 617-621.
| Animal experiment [1]: | |
Animal models | Sprague Dawley rats |
Preparation Method | The study was designed to test 3 objectives: (1) Prevention by Aviptadil: Two groups of rats were injected with monocrotaline (MCT) (a single s.c. injection of 60mg/kg). Group 1 rats received no additional treatment; group 2 rats received Aviptadil at 500μg/kg, i.p. (in 0.2mL PBS), every other day for 3 weeks, beginning the same day as MCT, for a total of 10 injections. A third group of 10 rats, serving as controls, received neither MCT nor Aviptadil. Survival was monitored for 45 days in a fourth group of 8 rats that received a single dose of MCT plus Aviptadil. (2) Reversal by Aviptadil or Bosentan: A group of 10 rats received Aviptadil at 500μg/kg, i.p., every other day for 3 weeks, beginning 3 weeks after the injection of MCT, i.e., after PAH pathology had already developed. Another group received Bosentan at 300mg/kg/day, as food admix for 3 weeks, beginning 3 weeks after MCT. (3) Reversal by combination therapy: Three weeks after MCT injection, another group of rats received both Aviptadil and Bosentan, as above, also for 3 weeks. |
Dosage form | 500μg/kg; i.p. |
Applications | Aviptadil completely prevented and significantly reversed MCT-induced pulmonary arterial hypertension (PAH). Aviptadil and Bosentan have synergistic effects. |
References: | |
| Cas No. | 40077-57-4 | SDF | |
| Überlieferungen | Vasoactive Intestinal Peptide (human, rat, mouse, rabbit, canine, porcine) | ||
| Formula | C147H238N44O42S | M.Wt | 3325.83 |
| Löslichkeit | Soluble 1 mg/ml in water | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 300.7 μL | 1.5034 mL | 3.0068 mL |
| 5 mM | 60.1 μL | 300.7 μL | 601.4 μL |
| 10 mM | 30.1 μL | 150.3 μL | 300.7 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 39 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *